PARIS--(Marketwire - March 27, 2012) - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the endomicroscopy market, today announced the appointment of industry veteran Georges Tabary as Vice President of Sales for the Europe, Middle East, and Africa (EMEA) region. Tabary will focus on structuring an elite sales force and implementing the company's sales strategy for its flagship Cellvizio® products in the EMEA region.
"We are delighted to welcome Georges to this key leadership position on our global sales team. He has a proven track record from a quarter century leading sales and marketing strategy for pioneering medical technology companies such as Leica Microsystems, Intuitive Surgical, Technomed International and ELA Medical," said Sacha Loiseau, Ph.D., CEO and founder of Mauna Kea Technologies. "At Intuitive Surgical, Georges not only led the sale of the first 50 da Vinci Surgical Systems outside the U.S. but also spear-headed the company's shift towards urology applications, leading to the company's overwhelming success in that market."
"I am delighted to be joining a bold and innovative team whose technology has tremendous potential to have a deep impact on how physicians diagnose and treat patients with digestive and respiratory diseases," Mr. Tabary said. "I'm very proud to be able to bring my experience to Mauna Kea Technologies, a company that is currently at the heart of a medical revolution within advanced endoscopy."
Mr. Tabary comes to Mauna Kea from Leica Microsystems where he was Director of Sales, Europe for 7 years, leading the company's surgical microscopy and histopathology businesses, overseeing strong growth in both areas.
Prior to Leica, Mr. Tabary served as Vice President and General Manager for Intuitive Surgical Europe. Mr. Tabary also spent almost 10 years in Japan where he was Managing Director for Technomed and Healthcare Business General Manager for Air Liquide Asia.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com